Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Details Narrative)

v3.20.1
Significant Accounting Policies (Details Narrative)
3 Months Ended 12 Months Ended
Mar. 31, 2020
USD ($)
Breathalyzers
shares
Mar. 31, 2019
USD ($)
Breathalyzers
shares
Dec. 31, 2019
USD ($)
Breathalyzers
Jan. 02, 2020
USD ($)
Restricted cash $ 115,094   $ 115,094  
Maturities of securities less than one year      
Increase in unrealized loss on securities $ 240,937 $ 240,937    
Increase in unrealized gain on securities 29,343 29,343    
Loss on sale of securities 36,714    
Proceeds from sale of marketable securities 2,303,890 852,520    
Allowances for doubtful accounts for trade receivables 458,902   458,902  
Bad debt expenses 4,247    
Depreciation expense 6,896 5,434    
Operating lease, annual rentals $ 132,000      
Operating lease description The Company leases its facility in West Deptford, New Jersey (the "Thorofare Facility") under an operating lease ("Thorofare Lease") with annual rentals of $132,000 plus common area maintenance (CAM) charges. The Thorofare Facility houses the Company's office, manufacturing, laboratories and warehouse space. The lease, took effect on January 1, 2008. On January 7, 2013, the Company extended its lease agreement for a term of 7 years, expiring December 31 2019. On November 11, 2019, the Company entered into an extension of the Thorofare Lease, extending the term to December 31, 2021, effective January 1, 2020, and providing for an early termination option of the lease with a 150 day notice period.      
Right-of-Use Asset $ 269,337   $ 306,706
Operating lease, liability 270,465      
Intangible assets 158,597   170,423  
Amortization expense 8,874 10,003    
Rebates recognized during period 200   20,002  
Rebates and incentives expense $ 664 8,698    
Income tax examination, likelihood percentage The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.      
Unrecognized tax benefits    
Income tax benefit    
Accrued for penalties and interest    
Shipping and handling cost 9,057 12,486    
Product cost of sales 172,871 245,937    
Net loss attributable to common shareholders $ 3,538,536 $ 916,958    
Weighted average basic and diluted common shares outstanding | shares 2,226,847 540,628    
Shipping and Handling [Member]        
Product cost of sales $ 11,919 $ 12,657    
Patents, Trademarks and Customer Lists [Member]        
Intangible assets 3,897,635   3,897,635  
Amortization expense $ 3,739,038   $ 3,727,212  
Topic 842 [Member]        
Right-of-Use Asset       306,706
Operating lease, liability       $ 306,706
Sales Revenue, Net [Member] | Customer One [Member]        
Concentration risk percentage 60.00% 45.00%    
Sales Revenue, Net [Member] | Customer Two [Member]        
Concentration risk percentage 35.00% 44.00%    
Sales Revenue, Net [Member] | Two Customers [Member]        
Concentration risk percentage 95.00% 89.00%    
Concentration risk, number of customer | Breathalyzers 2 2    
Trade Receivable [Member] | Customer One [Member]        
Concentration risk percentage 65.00%   30.00%  
Trade Receivable [Member] | Customer Two [Member]        
Concentration risk percentage 30.00%   18.00%  
Trade Receivable [Member] | Two Customers [Member]        
Concentration risk percentage 95.00%      
Concentration risk, number of customer | Breathalyzers 2      
Trade Receivable [Member] | Customer Three [Member]        
Concentration risk percentage     12.00%  
Trade Receivable [Member] | Customer Four [Member]        
Concentration risk percentage     12.00%  
Trade Receivable [Member] | Customer Five [Member]        
Concentration risk percentage     11.00%  
Trade Receivable [Member] | Five Customers [Member]        
Concentration risk percentage     83.00%  
Concentration risk, number of customer | Breathalyzers     5  
Accounts Payable [Member]        
Concentration risk percentage   59.00%    
Concentration risk, number of supplier | Breathalyzers   2    
Accounts Payable [Member] | Suppliers One [Member]        
Concentration risk percentage 64.00% 47.00%    
Concentration risk, number of supplier | Breathalyzers 1      
Accounts Payable [Member] | Suppliers Two [Member]        
Concentration risk percentage   12.00%    
Accounts Payable [Member] | No Supplier [Member]        
Concentration risk percentage 10.00%   10.00%  
Minimum [Member]        
Normal credit terms extended to customers 30 days      
Maximum [Member]        
Normal credit terms extended to customers 90 days